The clinical research mission of the Lymphoma Program at Dana-Farber Brigham Cancer Center is to make the treatment of lymphoid malignancies more effective and targeted, while reducing toxicities. The program makes promising new therapies available to patients with a variety of lymphoid malignancies at every stage of disease, in a carefully monitored setting, through clinical trials.
The program’s research currently focuses on several areas, including:
Our team is also leading several clinical trials of CAR T-cell therapy for lymphoma.
Many members of the clinical research team also have active programs of laboratory-based investigation in lymphoid malignancies. Researchers work closely with other scientists within Harvard Medical School-affiliated institutions.
To make a referral to one of the below clinical trials, please call: 617-632-6246
Disease
Trial Description
Principal Investigator
High-risk large B-cell lymphoma
22-467/NCT05605899: An adaptive phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of axicabtagene ciloleucel versus standard of care therapy as first-line therapy in subjects with high-risk large B-cell lymphoma
Diffuse large B-cell lymphoma
Relapsed/refractory
24-253/NCT04970901: A phase 1b open-label study to evaluate the safety and anti-cancer activity of loncastuximab tesirine in combination with other anti-cancer agents in patients with relapsed or refractory B-cell non-hodgkin lymphoma
Follicular lymphoma
Marginal zone lymphoma
22-632/NCT05783596: A phase 2 study of glofitamab and obinutuzumab for first-line treatment of follicular lymphoma and marginal zone lymphoma
Follicular lymphoma
22-702/NCT05783609: A phase 2 study of epcoritamab and rituximab for first-line treatment of follicular lymphoma
Follicular lymphoma
Relapsed/refractory
22-271/NCT05371093: A phase 3 randomized, open-label, multicenter study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in subjects with relapsed/refractory follicular lymphoma
Mantle cell lymphoma
Newly diagnosed
21-040/NCT04855695: A phase 1/2 study of acalabrutinib, venetoclax, and obinutuzumab in patients with Relapsed/refractory and previously untreated mantle cell lymphoma
Mantle cell lymphoma
Relapsed/refractory
24-104/NCT06192888: Pilot study of glofitamab and lenalidomide in patients with relapsed or refractory mantle cell lymphoma previously treated with a BTK inhibitor
CLL, SLL
Newly Diagnosed
24-017/NCT06333262: A phase 2 study of fixed duration therapy with pirtobrutinib and obinutuzumab in previously untreated chronic lymphocytic leukemia (POP)
CLL, SLL
Relapsed/refractory
21-279/NCT05168930: A phase 2 trial of zanubrutinib and venetoclax in previously treated CLL/SLL patients
Richter’s transformation
23-429/NCT06043674: A phase 2 study of glofitamab as monotherapy or in combination with polatuzumab vedotin or atezolizumab in Richter’s transformation
Hodgkin lymphoma
23-553/NCT05675410: A randomized phase 3 interim response adapted trial comparing standard therapy with immunooncology therapy for children and adults with newly diagnosed stage I and II classic Hodgkin lymphoma
Hodgkin lymphoma
Relapsed/refractory
22-121/NCT04561206: A phase 2 study of brentuximab vedotin plus nivolumab without stem cell consolidation in patients with relapsed/refractory classical Hodgkin lymphoma
T-cell lymphoma
23-320/NCT04803201: A randomized phase ii study of CHO(E)P vs CC-486-CHO(E)P vs duvelisib-CHO(E)P in previously untreated CD30 negative peripheral T-cell lymphomas
Primary mediastinal large B-cell lymphoma
EBV+ diffuse large B-cell lymphoma
T-cell histiocyte rich large B-cell lymphoma
Relapsed/refractory
23-179/NCT05934448: A phase II trial of pembrolizumab in combination with chimeric antigen receptor therapy in patients with relapsed/refractory primary mediastinal B-cell lymphoma
